ArticleJournal of cellular and molecular medicine2025
miR-486-5p Inhibits eNOS and Angiogenesis in Cultured Endothelial Cells by Targeting MAML3.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MiR-582-3p regulates endothelial cell function in lower extremity deep vein thrombosis by targeting TFRC.Annals of hematology · 2026Article
- Nanoparticle-delivered miR-486-5p inhibits HNanoscale advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Kidney ischemia-reperfusion (I/R) is associated with endothelial injury. Administration of miRNA (miR)-486-5p protects against rat kidney I/R injury, with localisation to capillary endothelial cells, although it inhibits I/R-induced endothelial nitric oxide synthase (eNOS) protein expression. Here, we studied the effect of miR-486-5p on eNOS and endothelial cell function and determined its mRNA targets. Human umbilical vein endothelial cells (HUVECs) were transfected with the miR-486-5p mimic and assayed for proliferation, migration and network formation. Biotinylated miR-486-5p was transfected for pulldown of bound mRNA, followed by RNA sequencing. miR-486-5p markedly decreased eNOS mRNA and protein in HUVECs (p < 0.001) and decreased eNOS protein in human pulmonary microvascular endothelial cells (p < 0.05), although eNOS was not a direct target of miR-486-5p. miR-486-5p inhibited angiogenesis, which was rescued with eNOS plasmid transfection. RNA sequencing of biotinylated miR-486-5p pulldown RNA revealed highly significant enrichment in predicted targets FOXO1, FOXP1, TNFSF4, MAML3 and CELSR3, and in the non-predicted target SPCS2. RT-qPCR validated these transcripts as inhibited by miR-486-5p. While silencing of FOXO1 had no impact on eNOS protein, MAML3 silencing inhibited eNOS levels. miR-486-5p inhibits angiogenesis in endothelial cells via eNOS down-regulation, which involves selective targeting of MAML3. These data support a novel pathway regulating endothelial cell function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.